

World Journal of *Gastroenterology*

World J Gastroenterol 2020 September 28; 26(36): 5387-5533



OPINION REVIEW

- 5387 COVID-19 pandemic and challenges in pediatric gastroenterology practice
Kriem J, Rahhal R

MINIREVIEWS

- 5395 Treatment of eosinophilic esophagitis with swallowed topical corticosteroids
Nennstiel S, Schlag C
- 5408 Artificial intelligence in gastric cancer: Application and future perspectives
Niu PH, Zhao LL, Wu HL, Zhao DB, Chen YT

ORIGINAL ARTICLE**Basic Study**

- 5420 Granulocyte-macrophage colony-stimulating factor protects mice against hepatocellular carcinoma by ameliorating intestinal dysbiosis and attenuating inflammation
Wu YN, Zhang L, Chen T, Li X, He LH, Liu GX

Retrospective Study

- 5437 Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability
Bohra A, Rizvi QAA, Keung CYY, Vasudevan A, van Langenberg DR
- 5450 Histopathological validation of magnifying endoscopy for diagnosis of mixed-histological-type early gastric cancer
Ozeki Y, Hirasawa K, Kobayashi R, Sato C, Tateishi Y, Sawada A, Ikeda R, Nishio M, Fukuchi T, Makazu M, Taguri M, Maeda S

Observational Study

- 5463 Major gastrointestinal bleeding and antithrombotics: Characteristics and management
Bouget J, Viglino D, Yvetot Q, Oger E
- 5474 Pediatric non-alcoholic fatty liver disease and kidney function: Effect of HSD17B13 variant
Di Sessa A, Umamo GR, Cirillo G, Passaro AP, Verde V, Cozzolino D, Guarino S, Marzuillo P, Miraglia del Giudice E
- 5484 Motility index measured by magnetic resonance enterography is associated with sex and mural thickness
Månsson S, Ekberg O, Ohlsson B
- 5498 Impact of B-mode-ultrasound-guided transhepatic and transperitoneal cholecystostomy tube placement on laparoscopic cholecystectomy
Liu P, Liu C, Wu YT, Zhu JY, Zhao WC, Li JB, Zhang H, Yang YX

Prospective Study

- 5508** Effects of early oral feeding after radical total gastrectomy in gastric cancer patients

Lu YX, Wang YJ, Xie TY, Li S, Wu D, Li XG, Song QY, Wang LP, Guan D, Wang XX

CASE REPORT

- 5520** SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma mimicking solid pseudopapillary neoplasm: A case report and review of the literature

Hua Y, Soni P, Larsen D, Zreik R, Leng B, Rampisela D

- 5527** Solitary peritoneal metastasis of gastrointestinal stromal tumor: A case report

Sugiyama Y, Shimbara K, Sasaki M, Kouyama M, Tazaki T, Takahashi S, Nakamitsu A

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Dr. José M Ramia is Head of Department (Surgery) in Hospital General Universitario de Alicante (Spain), since June 2020. Dr. Ramia undertook his surgical residency program at Hospital 12 de Octubre (Madrid) (1991-1995), receiving his PhD in 1999 (Universidad Complutense, Madrid). He has published 310 articles in medical journals and 25 books chapters. His research interests involve every surgical topic of liver, bile duct and pancreas diseases and liver transplantation. He is the current President of the Spanish Chapter of International Hepato-pancreato Biliary Association (HPBA), member of the Educational Committee and Scientific and Research Committee of European-African HPBA, and examiner for the HPB FEBS Board. Dr Ramia is a fellow of the American College of Surgeons, Royal College of Surgeons (England) and European Board of Surgery-HPB. (L-Editor: Filipodia)

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (*WJG*, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. *WJG* mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The *WJG* is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2020 edition of Journal Citation Report® cites the 2019 impact factor (IF) for *WJG* as 3.665; IF without journal self cites: 3.534; 5-year IF: 4.048; Ranking: 35 among 88 journals in gastroenterology and hepatology; and Quartile category: Q2.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Yan-Liang Zhang; Production Department Director: Yun-Xiaojuan Wu; Editorial Office Director: Ze-Mao Gong.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski, Subrata Ghosh

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

September 28, 2020

COPYRIGHT

© 2020 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma mimicking solid pseudopapillary neoplasm: A case report and review of the literature

Yinan Hua, Piyush Soni, Douglas Larsen, Riyam Zreik, Bing Leng, Debby Rampisela

ORCID number: Yinan Hua 0000-0003-3549-3506; Piyush Soni 0000-0002-8927-5013; Douglas Larsen 0000-0003-1392-0626; Riyam Zreik 0000-0002-2437-5056; Bing Leng 0000-0001-8262-1852; Debby Rampisela 0000-0002-7559-1779.

Author contributions: All authors contributed to the writing and revising of the manuscript.

Informed consent statement: Informed written consent was obtained.

Conflict-of-interest statement: No conflict of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works

Yinan Hua, Piyush Soni, Douglas Larsen, Riyam Zreik, Bing Leng, Debby Rampisela, Department of Pathology, Baylor Scott & White Health, Texas A&M University College of Medicine, Temple, TX 76508, United States

Corresponding author: Debby Rampisela, MD, Attending Doctor, Department of Pathology, Baylor Scott & White Health, Texas A&M University College of Medicine, 2401 S. 31st Street, MS-01-266, Temple, TX 76508, United States. debby.rampisela@bswhealth.org

Abstract

BACKGROUND

SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma is a very aggressive tumor that is rarely reported in the literature. The tumor has a predominant rhabdoid cell component and different patterns of growth have been reported.

CASE SUMMARY

A 59-year-old woman presented with diffuse abdominal pain, increasing in severity and accompanied by weight loss, nausea, and vomiting. Imaging showed a pancreatic head mass. Fine needle aspiration demonstrated atypical epithelioid cells with a pseudopapillary growth pattern suggestive of solid pseudopapillary neoplasm. The excised neoplasm showed monotonous epithelioid and focally spindle cells with pseudopapillary structures, rhabdoid features, and loss of SMARCB1 protein expression with wild-type *KRAS*, consistent with a SMARCB1/INI1-deficient undifferentiated rhabdoid carcinoma. The patient's condition deteriorated rapidly following surgery and she expired 3 mo post operation.

CONCLUSION

In this article, we report the first case of SMARCB1/INI1-deficient undifferentiated pancreatic rhabdoid carcinoma mimicking solid pseudopapillary neoplasm.

Key Words: Pancreatic undifferentiated rhabdoid carcinoma; Solid pseudopapillary neoplasm; SMARCB1/INI1; *KRAS*; Case report

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Received: June 10, 2020

Peer-review started: June 11, 2020

First decision: June 18, 2020

Revised: June 29, 2020

Accepted: September 5, 2020

Article in press: September 5, 2020

Published online: September 28, 2020

P-Reviewer: Carloni R

S-Editor: Wang JL

L-Editor: A

P-Editor: Zhang YL



Core Tip: The presence of a pseudopapillary architectural pattern in pancreatic tumors sampled via fine needle aspiration commonly leads to solid pseudopapillary neoplasm as the primary diagnostic consideration, particularly in middle-aged women; however, an inconclusive immunohistochemistry profile may suggest an alternative diagnosis. Our case highlights that while SMARCB1/INI1-deficient pancreatic undifferentiated carcinomas may mimic solid pseudopapillary neoplasm, recognition of this aggressive malignancy is important as these rare tumors impart a dismal prognosis.

Citation: Hua Y, Soni P, Larsen D, Zreik R, Leng B, Rampisela D. SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma mimicking solid pseudopapillary neoplasm: A case report and review of the literature. *World J Gastroenterol* 2020; 26(36): 5520-5526

URL: <https://www.wjgnet.com/1007-9327/full/v26/i36/5520.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v26.i36.5520>

INTRODUCTION

Pancreatic undifferentiated carcinoma is a group of neoplasms comprised of pleomorphic giant cell carcinoma, sarcomatoid carcinoma, rhabdoid carcinoma, and round cell carcinomas. Pancreatic undifferentiated rhabdoid carcinoma, characterized by a predominant rhabdoid cell component, is a very rare tumor with high lethality. Patients often die within weeks or months of diagnosis. The first case of pancreatic rhabdoid carcinoma was reported in 1997^[1]. A recent study by Agaimy *et al*^[2] reported the phenotypic and molecular heterogeneity of pancreatic undifferentiated rhabdoid carcinoma. Two subtypes of the tumor were described based on the tumor's *KRAS* status and SMARCB1 expression. The pleomorphic giant cell subtype displays *KRAS* alterations with preservation of SMARCB1 expression; in contrast, the anaplastic monomorphic subtype shows absence of *KRAS* alterations with loss of SMARCB1 expression. To our best knowledge, eight SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinomas have been reported in the literature^[2-6]. Our case is the first reported case with a solid and pseudopapillary growth pattern mimicking solid pseudopapillary neoplasm (SPN).

CASE PRESENTATION

Chief complaints

A 59-year-old woman presented to the clinic with diffuse abdominal pain.

History of present illness

The patient complained of diffuse abdominal pain with increased intensity for approximately 4 wk, accompanied by weight loss, nausea, and vomiting.

History of past illness

The patient had a past medical history of back pain, gastroesophageal reflux disease, allergic rhinitis and hepatitis A; and a past surgical history of appendectomy, cholecystectomy, Cesarean section, and ovarian cyst removal.

Physical examination

The abdomen was soft, nondistended, but tender to palpation in the right upper quadrant with no rebound or guarding. A well-healed scar was noted below the umbilicus midline, intersecting with a Cesarean section scar.

Laboratory examinations

The patient had elevated laboratory values of alkaline phosphatase and aspartate aminotransferase.

Imaging examinations

The patient underwent a computed topography (CT) scan of abdomen and pelvis, and an abdominal magnetic resonance imaging (MRI) scan. CT scan revealed a hypodense

region in the head of the pancreas, and the follow-up MRI revealed a 3.1 cm pancreatic head mass. Endoscopic ultrasound-guided fine needle aspiration (FNA) of the pancreatic mass was performed and a diagnosis of low-grade neoplasm with papillary features most suggestive of a SPN was rendered.

Pathological findings

The FNA specimen was hypercellular with a prominent pseudopapillary growth pattern (Figure 1A). Abundant discohesive tumor cells were also present. The tumor cells were small to intermediate-sized, predominantly epithelioid with round to oval nuclei, inconspicuous to prominent nucleoli, and focal nuclear grooves. Some tumor cells exhibited eccentric nuclei, prominent nucleoli and large cytoplasmic vacuoles (Figure 1B). The tumor cells on the cell block section showed eosinophilic cytoplasm with no obvious rhabdoid features. Immunohistochemically, the tumor cells were diffusely positive for vimentin, very focally positive for synaptophysin and pankeratin (AE1/AE3), and negative for CD10, progesterone receptor, alpha 1-antitrypsin, CD56 and chromogranin. No nuclear beta-catenin stain was noted. Although the immunohistochemical profile was not conclusive, a diagnosis of a low grade neoplasm with papillary features most suggestive of SPN was made.

The enucleated pancreatic mass was received in two parts, measuring 3.4 cm × 2.4 cm × 1.1 cm and 2.0 cm × 1.0 cm × 0.4 cm. Histological sections showed a heterogeneous tumor with areas of solid and pseudopapillary growth and focal hemorrhage (Figure 2A). A subpopulation of the neoplastic cells was intermediate-sized, epithelioid and focally spindled with mild to moderate nuclear pleomorphism and indistinct to prominent nucleoli. Nuclear grooves were focally appreciated. However, a second subpopulation (approximately 60% of the neoplastic cells) showed rhabdoid features with eccentrically located nuclei, prominent nucleoli, abundant eosinophilic cytoplasm and eosinophilic cytoplasmic inclusions (Figure 2B). By immunohistochemistry, the neoplastic cells were diffusely positive for vimentin and focally positive for pankeratin (AE1/AE3), OSCAR keratin, CD34, Cyclin D1, synaptophysin and CD56. The tumor cells were negative for DOG1, CD117/KIT, desmin, STAT6, progesterone receptor, neuron-specific enolase, trypsin, chromogranin, CD99, CD10, SOX10, and S100. Beta-catenin immunostaining showed focal loss of membranous expression without nuclear expression. E-cadherin immunostaining showed patchy loss of membranous expression. The proliferation index Ki-67 demonstrated variable expression, ranging from less than 10% (non-rhabdoid cells) to over 50% (rhabdoid cells). PD-L1 highlighted less than 1% tumor cells, which was interpreted as negative for PD-L1 expression. SMARCB1/INI1 immunostaining showed complete loss of nuclear staining in all tumor cells. Next generation sequencing using the Ion AmpliSeq™ Cancer Hotspot Panel v2 confirmed loss of SMARCB1 gene with wild type KRAS gene.

FINAL DIAGNOSIS

The final diagnosis was SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma.

TREATMENT

The patient was treated with pancreatic mass enucleation approximately 4 mo after the initial presentation of abdominal pain.

OUTCOME AND FOLLOW-UP

The patient's post operation course was complicated by small mesenteric artery (SMA) thrombosis, small bowel ischemia, perforated small bowel and intra-abdominal abscess. She underwent a small bowel resection, an open thrombectomy of the SMA and a placement of a drainage for the abdominal abscess. She was readmitted twice to the hospital following episodes of upper gastrointestinal bleeding due to multiple ulcers, which were treated with epinephrine injections and cauteries. Follow up CT of the abdomen and pelvis 1 mo and 2 mo post-pancreatic mass enucleation showed multiple intrahepatic cystic masses that increased in size, suspicious for malignancy.




Figure 1 Fine needle aspiration smears of the pancreatic tumor. A: Pseudopapillary growth pattern and discohesive tumor cells (Papanicolaou stain, 40 ×); B: Tumor cells with mild to moderate cytologic atypia and large intracytoplasmic vacuoles (Papanicolaou stain, 400 ×).




Figure 2 Histomorphology of enucleated pancreatic tumor. A: Pseudopapillary growth pattern (Hematoxylin and eosin stain, 40 ×); B: Tumor cells with rhabdoid features (Hematoxylin and eosin stain, 400 ×); C, D: Immunohistochemistry stains of vimentin (C) and SMARCB1/INI1 (D) (100 ×).

Subsequent core biopsy of the liver mass was consistent with a metastatic pancreatic undifferentiated rhabdoid carcinoma. The patient's condition deteriorated rapidly and she expired 3 mo after pancreatic mass enucleation.

DISCUSSION

SMARCB1/INI1, ubiquitously expressed in the nuclei of all normal cells, is an important player in the SWI/SNF ATP-dependent chromatin-remodeling complex^[7]. Cell biology studies have revealed a wide spectrum of signaling cascades regulated by SMARCB1, including p16-RB pathway, canonical WNT pathway, sonic hedgehog pathway, and polycomb pathway^[8]. More importantly, aberrant expression of SMARCB1 has been found in a variety of tumors^[7,9]. In particular, malignant rhabdoid tumor, epithelioid sarcoma, sinonasal carcinoma, renal medullary carcinoma, and pancreatic undifferentiated rhabdoid carcinoma can exhibit complete loss of SMARCB1 expression. SMARCB1 immunohistochemistry has been well established as a highly sensitive and specific tool for detecting malignant rhabdoid neoplasms^[9].

SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma is an aggressive and rare primary malignancy of the pancreas. According to the current World Health Organization classification of pancreatic tumors, undifferentiated pancreatic carcinoma is defined as a malignant epithelial neoplasm in which a

substantial component of the neoplasm does not show a definitive line of differentiation^[10]. The incidence of undifferentiated pancreatic carcinoma is only about 2% to 7% of all pancreatic cancers. A spectrum of histologic variants, including anaplastic rhabdoid carcinoma, sarcomatoid spindle cell carcinoma, carcinosarcoma with recognizable adenocarcinoma and high-grade spindle cell areas, as well as undifferentiated carcinoma with osteoclast-like giant cells, have been recognized^[1-6,11-17]. Agaimy *et al*^[2] pointed out that pancreatic undifferentiated rhabdoid carcinoma (undifferentiated carcinoma with rhabdoid features) showed heterogeneous morphology but could be separated into two subtypes: Pleomorphic giant cell subtype (positive for *KRAS* alterations and intact SMARCB1 expression) and anaplastic monomorphic cell subtype (loss of SMARCB1 expression and wild type *KRAS* expression). The prognosis of both subtypes of the undifferentiated rhabdoid carcinoma is poor (no reported cases with 5-year survival). In contrast, the undifferentiated carcinoma with osteoclastic giant cells appears to confer a more favorable prognosis with 5-year survival of approximately 50%^[18,19].

To our best knowledge, eight SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinomas have been reported in the literature (Table 1). Eight of the nine cases (including our case) had clinical data. The patients consisted of three males and five females, ranging from 35 to 76 years. Tumor sizes ranged from 1.9 cm to 10 cm. Five cases originated in the pancreatic head, two in the tail, and one in the body. Six cases had distant metastases and three were not specified. Six cases had follow up and all of the patients died of disease either post-operatively or within 2 wk to 7 mo following the initial diagnosis (mean: 3.6 mo, median: 3.5 mo). The histologic patterns of the tumors were heterogeneous with pseudopapillary acantholytic gland-like spaces, angiosarcoma-like, proximal-type epithelioid sarcoma-like, solid/diffuse, mucoid/myxoid stromal and solid patterns. Our case had solid and pseudopapillary features mimicking SPN. All nine cases had complete loss of SMARCB1 by immunohistochemistry. Six cases had wild-type *KRAS*, one was positive for *KRAS* mutation, and two cases were not tested. PD-L1 immunostaining were performed on two cases including our case, and both cases were negative for PD-L1 expression. Based on the limited number of the cases, the prognosis of SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma is dismal.

SPN is a rare low-grade malignant pancreatic neoplasm composed of poorly cohesive epithelial cells forming solid and pseudopapillary structures that lack of a specific line of pancreatic epithelial differentiation. The histology shows solid nests of poorly cohesive cells forming a cuff surrounding blood vessels, resulting in a pseudopapillary architecture. The stroma usually shows various degrees of hyalinization or evidence of degeneration such as hemorrhage, foamy macrophages, calcification and cholesterol clefts. The tumor cells usually have a moderate amount of eosinophilic cytoplasm with perinuclear vacuoles, relatively uniform nuclei with finely textured chromatin, inconspicuous nucleoli and longitudinal grooves, and often containing intracytoplasmic hyaline globules. High-grade malignant transformation of SPN with an aggressive clinical course has been reported^[20-23]. The morphological features predicting high-grade transformation include diffuse growth pattern, extensive tumor necrosis, significant nuclear atypia, high mitotic rate and presence of an undifferentiated component^[20], while typical histologic architecture and cytological features of a SPN are always present. The tumor cells of SPN express vimentin, CD56, alpha 1-antichymotrypsin, alpha 1-antitrypsin, cyclin D1, CD10 and progesterone receptor. The tumor cells may also show focal immunoreactivity for synaptophysin and cytokeratins. The tumor always shows beta-catenin mutation with nuclear and cytoplasmic staining for beta-catenin immunostaining, including areas of high-grade transformation^[20,24]. On the other hand, majority of the pancreatic undifferentiated carcinoma shows only diffuse positivity for vimentin and focal for cytokeratin^[10] with no nuclear immunoreactivity for beta-catenin. Although our case showed solid/pseudopapillary architecture and cytological features mimicking SPN, especially on the FNA specimen, the immunostaining pattern and molecular findings on the enucleation specimen did not support the diagnosis of SPN. The findings were consistent with a SMARCB1/INI1-deficient undifferentiated rhabdoid carcinoma.

CONCLUSION

In conclusion, here we report a rare case of SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma with cytological and architectural features mimicking SPN. Recognition of this entity is very important due to the poor prognosis

Table 1 Summary of SMARCB1 deficient pancreatic undifferentiated rhabdoid carcinoma cases in the literature along with our case

Ref.	Age/gender	Size/pancreatic location	Histology	Treatment	Metastasis	Outcome	KRAS mutation	SMARCB1 (IHC)
Agaimy <i>et al</i> ^[2]	76/M	5 cm/head	Rhabdoid	Surgery	NS	DOD in 1 mo	Wild type	Complete loss
Agaimy <i>et al</i> ^[2]	44/F	6 cm/head	Rhabdoid, angiosarcoma-like	Surgery	NS	NS	Positive (pGly12Asp)	Complete loss
Agaimy <i>et al</i> ^[2]	72/M	4 cm/head	Rhabdoid, pseudopapillary acantholytic gland-like spaces	Surgery	Liver, lymph nodes	DOD post-operatively	Wild type	Complete loss
Agaimy <i>et al</i> ^[2]	61/M	5 cm/tail	Rhabdoid, prominent neutrophils and focal glandular formation	Surgery	Intra-abdominal, stomach	NS	Wild type	Complete loss
Sano <i>et al</i> ^[3]	68/F	10 cm/body, tail	Rhabdoid	Palliative	Liver, kidneys, lungs, right adrenal gland, omentum, peritoneum	DOD in 2 wk	NS	Complete loss
Ohike <i>et al</i> ^[4]	35/F	6 cm/head	Rhabdoid, solid/diffuse	Chemo	Liver	DOD in 7 mo	Wild type	Complete loss
Tahara <i>et al</i> ^[5]	67/F	1.9 cm/body	Rhabdoid, solid/diffuse	Chemo	Liver, lung, bone, tongue, right thigh	DOD in half year	Wild type	Complete loss
Lehrke <i>et al</i> ^[6]	NS	NS	Rhabdoid	NS	NS	NS	NS	Complete loss
Our case	59/F	3.1 cm/head	Rhabdoid, solid pseudopapillary-like	Surgery	Liver	DOD in 7 mo	Wild type	Complete loss

KRAS: KRAS proto-oncogene GTPase; Chemo: Chemotherapy; DOD: Died of disease; NS: Not specified; IHC: Immunohistochemistry.

of undifferentiated rhabdoid carcinoma compared to SPN, which has much better prognosis. More studies are warranted for the better understanding of pancreatic undifferentiated rhabdoid carcinoma, particularly the SMARCB1/INI1-deficient subtype.

ACKNOWLEDGEMENTS

We thank Dr. Rondell Graham at Mayo Clinic for his expertise.

REFERENCES

- Nishihara K, Katsumoto F, Kurokawa Y, Toyoshima S, Takeda S, Abe R. Anaplastic carcinoma showing rhabdoid features combined with mucinous cystadenocarcinoma of the pancreas. *Arch Pathol Lab Med* 1997; **121**: 1104-1107 [PMID: 9341593]
- Agaimy A, Haller F, Frohnauer J, Schaefer IM, Ströbel P, Hartmann A, Stoehr R, Klöppel G. Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes. *Mod Pathol* 2015; **28**: 248-260 [PMID: 25103069 DOI: 10.1038/modpathol.2014.100]
- Sano M, Homma T, Hayashi E, Noda H, Amano Y, Tsujimura R, Yamada T, Quattrochi B, Nemoto N. Clinicopathological characteristics of anaplastic carcinoma of the pancreas with rhabdoid features. *Virchows Arch* 2014; **465**: 531-538 [PMID: 25031015 DOI: 10.1007/s00428-014-1631-5]
- Ohike N, Suzuki R, Isobe T, Norose T, Shiohara A, Kunimura T, Kohashi K, Oda Y. A case of pancreatic undifferentiated carcinoma mimicking proximal-type epithelioid sarcoma. *J Pancreas* 2016; **17**: 75-80
- Tahara S, Takeyari M, Morii E. Usefulness of cytological analysis in the diagnosis of pancreatic undifferentiated rhabdoid carcinoma. *Pathol Int* 2018; **68**: 56-58 [PMID: 29235210 DOI: 10.1111/pin.12616]
- Lehrke HD, Graham RP, McWilliams RR, Lam-Himlin DM, Smyrk TC, Jenkins S, Dong H, Zhang L. Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells. *Am J Clin Pathol* 2017; **148**: 441-449 [PMID: 29069274 DOI: 10.1093/ajcp/aqx092]
- Hollmann TJ, Hornick JL. INI1-deficient tumors: diagnostic features and molecular genetics. *Am J Surg Pathol* 2011; **35**: e47-e63 [PMID: 21934399 DOI: 10.1097/PAS.0b013e31822b325b]
- Kohashi K, Oda Y. Oncogenic roles of SMARCB1/INI1 and its deficient tumors. *Cancer Sci* 2017; **108**: 547-552 [PMID: 28109176 DOI: 10.1111/cas.13173]
- Agaimy A. The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic,

- biological, and molecular heterogeneity. *Adv Anat Pathol* 2014; **21**: 394-410 [PMID: 25299309 DOI: 10.1097/PAP.000000000000038]
- 10 **Hruban RH**, Adsay NV, Esposito I. Pancreatic ductal adenocarcinoma. World Health Organization Classification of Tumor. Digestive System Tumours. 5th Edition. Lyon: IARC Press, 2019; 322-332
 - 11 **Kuroda N**, Sawada T, Miyazaki E, Hayashi Y, Toi M, Naruse K, Fukui T, Nakayama H, Hiroi M, Taguchi H, Enzan H. Anaplastic carcinoma of the pancreas with rhabdoid features. *Pathol Int* 2000; **50**: 57-62 [PMID: 10692179 DOI: 10.1046/j.1440-1827.2000.00996.x]
 - 12 **Chadha MK**, LeVea C, Javle M, Kuvshinoff B, Vijaykumar R, Iyer R. Anaplastic pancreatic carcinoma. A case report and review of literature. *JOP* 2004; **5**: 512-515 [PMID: 15536293]
 - 13 **Cho YM**, Choi J, Lee OJ, Lee HI, Han DJ, Ro JY. SMARCB1/INI1 missense mutation in mucinous carcinoma with rhabdoid features. *Pathol Int* 2006; **56**: 702-706 [PMID: 17040295 DOI: 10.1111/j.1440-1827.2006.02033.x]
 - 14 **Jamali M**, Serra S, Chetty R. Adenosquamous carcinoma of the pancreas with clear cell and rhabdoid components. A case report. *JOP* 2007; **8**: 330-334 [PMID: 17495363]
 - 15 **Kuroda N**, Iwamura S, Fujishima N, Ohara M, Hirouchi T, Mizuno K, Hayashi Y, Lee GH. Anaplastic carcinoma of the pancreas with rhabdoid features and hyaline globule-like structures. *Med Mol Morphol* 2007; **40**: 168-171 [PMID: 17874050 DOI: 10.1007/s00795-006-0349-0]
 - 16 **Al-Nafussi A**, O'Donnell M. Poorly differentiated adenocarcinoma with extensive rhabdoid differentiation: clinicopathological features of two cases arising in the gastrointestinal tract. *Pathol Int* 1999; **49**: 160-163 [PMID: 10355971 DOI: 10.1046/j.1440-1827.1999.00839.x]
 - 17 **Layfield LJ**, Bentz J. Giant-cell containing neoplasms of the pancreas: an aspiration cytology study. *Diagn Cytopathol* 2008; **36**: 238-244 [PMID: 18335561 DOI: 10.1002/dc.20785]
 - 18 **Paniccia A**, Hosokawa PW, Schulick RD, Henderson W, Kaplan J, Gajdos C. A matched-cohort analysis of 192 pancreatic anaplastic carcinomas and 960 pancreatic adenocarcinomas: A 13-year North American experience using the National Cancer Data Base (NCDB). *Surgery* 2016; **160**: 281-292 [PMID: 27085687 DOI: 10.1016/j.surg.2016.02.025]
 - 19 **Muraki T**, Reid MD, Basturk O, Jang KT, Bedolla G, Bagci P, Mittal P, Memis B, Katabi N, Bandyopadhyay S, Sarmiento JM, Krasinskas A, Klimstra DS, Adsay V. Undifferentiated Carcinoma With Osteoclastic Giant Cells of the Pancreas: Clinicopathologic Analysis of 38 Cases Highlights a More Protracted Clinical Course Than Currently Appreciated. *Am J Surg Pathol* 2016; **40**: 1203-1216 [PMID: 27508975 DOI: 10.1097/PAS.0000000000000689]
 - 20 **Tang LH**, Aydin H, Brennan MF, Klimstra DS. Clinically aggressive solid pseudopapillary tumors of the pancreas: a report of two cases with components of undifferentiated carcinoma and a comparative clinicopathologic analysis of 34 conventional cases. *Am J Surg Pathol* 2005; **29**: 512-519 [PMID: 15767807 DOI: 10.1097/01.pas.0000155159.28530.88]
 - 21 **Matsuo H**, Ikoma H, Morimura R, Arita T, Kosuga T, Konishi H, Murayama Y, Komatsu S, Shiozaki A, Kuriu Y, Nakanishi M, Ichikawa D, Fujiwara H, Okamoto K, Otsuji E. [A Case Report of an Undifferentiated Pancreatic Carcinoma Diagnosed as a Solid Pseudopapillary Neoplasm before Surgery]. *Gan To Kagaku Ryoho* 2016; **43**: 2350-2352 [PMID: 28133318]
 - 22 **Kim JH**, Lee JM. Clinicopathologic Review of 31 Cases of Solid Pseudopapillary Pancreatic Tumors: Can We Use the Scoring System of Microscopic Features for Suggesting Clinically Malignant Potential? *Am Surg* 2016; **82**: 308-313 [PMID: 27097622 DOI: 10.1177/000313481608200414]
 - 23 **Tomioka K**, Ohike N, Aoki T, Enami Y, Fujimori A, Koizumi T, Kusano T, Nogaki K, Tashiro Y, Wada Y, Hakozaiki T, Shibata H, Hirai T, Yamazaki T, Fujimasa K, Norose T, Isobe T, Murakami M. Solid Pseudopapillary Neoplasm of the Pancreas with High-Grade Malignant Transformation Involving p16-RB Pathway Alterations. *Case Rep Surg* 2020; **2020**: 5980382 [PMID: 32158585 DOI: 10.1155/2020/5980382]
 - 24 **Tanaka Y**, Kato K, Notohara K, Hojo H, Ijiri R, Miyake T, Nagahara N, Sasaki F, Kitagawa N, Nakatani Y, Kobayashi Y. Frequent beta-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm. *Cancer Res* 2001; **61**: 8401-8404 [PMID: 11731417]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

